Investors Purchase Large Volume of Call Options on Compass Pathways (NASDAQ:CMPS)

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) was the target of some unusual options trading activity on Monday. Investors acquired 5,436 call options on the stock. This represents an increase of 77% compared to the average volume of 3,069 call options.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Persistent Asset Partners Ltd acquired a new position in shares of Compass Pathways in the fourth quarter valued at approximately $38,000. Advisory Services Network LLC acquired a new position in shares of Compass Pathways in the third quarter valued at approximately $41,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Compass Pathways in the fourth quarter valued at approximately $47,000. BIT Capital GmbH acquired a new position in shares of Compass Pathways in the third quarter valued at approximately $54,000. Finally, Northeast Financial Consultants Inc acquired a new position in shares of Compass Pathways in the second quarter valued at approximately $59,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on CMPS. Canaccord Genuity Group dropped their target price on shares of Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, March 26th. Morgan Stanley dropped their target price on shares of Compass Pathways from $18.00 to $16.00 and set an “overweight” rating for the company in a research report on Wednesday, March 25th. Compass Point set a $15.00 target price on shares of Compass Pathways in a research report on Thursday, February 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. Finally, HC Wainwright boosted their price objective on shares of Compass Pathways from $40.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.63.

Compass Pathways Trading Up 40.9%

NASDAQ CMPS traded up $2.72 during trading on Monday, reaching $9.38. 13,580,094 shares of the stock traded hands, compared to its average volume of 2,935,838. The firm has a market cap of $900.83 million, a price-to-earnings ratio of -3.04 and a beta of 2.01. The stock’s 50-day moving average price is $6.37 and its 200 day moving average price is $6.36. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 0.55. Compass Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $10.21.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Tuesday, March 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.59). Analysts predict that Compass Pathways will post -2.33 EPS for the current year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.